Evidence map›Paper›PMID 33106780›Full record

ReviewMaterials today. Chemistry2020

Potential of graphene-based materials to combat COVID-19: properties, perspectives, and prospects.

A K Srivastava, N Dwivedi, C Dhand, R Khan, N Sathish, M K Gupta, R Kumar, S Kumar

Abstract readReview
In one paragraph

Review in Materials today. Chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. COVID-19 diagnostics: Molecular biology to nanomaterials.Clinica chimica acta; international journal of clinical chemistry · 2023
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A K SrivastavaCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.
N DwivediCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.
C DhandCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.
R KhanCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.
N SathishCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.
M K GuptaCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.
R KumarCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.
S KumarCSIR-Advanced Materials and Processes Research Institute, Bhopal, 462026, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new virus in the coronavirus family that causes coronavirus disease (COVID-19), emerges as a big threat to the human race. To date, there is no medicine and vaccine available for COVID-19 treatment. While the development of medicines and vaccines are essentially and urgently required, what is also extremely important is the repurposing of smart materials to design effective systems for combating COVID-19. Graphene and graphene-related materials (GRMs) exhibit extraordinary physicochemical, electrical, optical, antiviral, antimicrobial, and other fascinating properties that warrant them as potential candidates for designing and development of high-performance components and devices required for COVID-19 pandemic and other futuristic calamities. In this article, we discuss the potential of graphene and GRMs for healthcare applications and how they may contribute to fighting against COVID-19.

Indexed as

MaterialsMicrobeSARS-CoV-2Virus

Identifiers

PMID33106780
PMCPMC7577689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.